Why is Panacea Biotec falling/rising?

Recent Price Movement and Market Performance

Panacea Biotec’s shares have been under pressure in recent sessions, falling for three consecutive days and losing 4.75% over this period. The stock underperformed its sector by 1.1% on the day, touching an intraday low of ₹351.25, down 3.2%. Notably, the share price is trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling a bearish technical outlook. Investor participation has also waned, with delivery volumes on 01 Dec dropping sharply by 79.01% compared to the five-day average, indicating reduced buying interest from market participants.

Long-Term Returns and Relative Underperformance

Over the past year, Panacea Biotec’s stock has delivered a negative return of 23.26%, significantly lagging behind the Sensex, which gained 6.09% during the same period. Year-to-date, the stock is down 13.46%, while the benchmark index has risen by 8.96%. Even over the last month, the stock declined by 18.01%, contrasting with the Sensex’s modest 1.43% gain. Although the company has shown strong gains over a three-year horizon with a 153.55% return, this is overshadowed by the recent poor performance and weak fundamentals that have weighed heavily on investor sentiment.

Fundamental Weaknesses and Financial Struggles

Panacea Biotec’s recent financial results have been a major factor behind the stock’s decline. The company reported a significant operating loss, with net sales shrinking at an annual rate of 0.13% over the last five years and operating profit plummeting by 218.34% during the same period. The firm’s ability to service its debt is notably weak, reflected in a poor average EBIT to interest ratio of -9.36, indicating that earnings before interest and taxes are insufficient to cover interest expenses.

Quarterly results for September 2025 further highlight the company’s challenges. Profit before tax excluding other income stood at a loss of ₹28.27 crore, a staggering decline of 962.78%, while net profit after tax plunged by 907.2% to a loss of ₹16.62 crore. Additionally, cash and cash equivalents at the half-year mark were at a low ₹81.61 crore, raising concerns about liquidity and operational sustainability.

Risk Profile and Market Sentiment

The stock’s negative earnings before interest, taxes, depreciation, and amortisation (EBITDA) position adds to its risk profile, making it less attractive compared to its historical valuations. Over the past year, profits have fallen by nearly 80%, while the stock’s price has declined by over 23%, signalling deteriorating fundamentals that have not been offset by market optimism. This has led to the stock underperforming the broader market indices, including the BSE500, which posted a 3.93% return in the last year.

Institutional Interest Amidst Weakness

Despite the negative trends, institutional investors have marginally increased their stake in Panacea Biotec by 0.55% over the previous quarter, now collectively holding 2.86% of the company. This suggests some confidence from well-resourced investors who may be analysing the company’s fundamentals more closely. However, this incremental participation has not been sufficient to reverse the stock’s downward trajectory in the short term.

Conclusion: Why Panacea Biotec Is Falling

In summary, Panacea Biotec’s recent share price decline is primarily driven by its weak financial performance, including sustained operating losses, sharply deteriorating profitability, and poor debt servicing capacity. The company’s negative quarterly earnings and low cash reserves have heightened investor concerns, leading to reduced participation and selling pressure. Although institutional investors have slightly increased their holdings, this has not been enough to offset the negative sentiment. The stock’s underperformance relative to key benchmarks and its position below all major moving averages further reinforce the bearish outlook. Investors should carefully consider these fundamental weaknesses before making investment decisions regarding Panacea Biotec.

Limited Time Only! Subscribe for Rs. 12,999 and get 1 Year of MojoOne + an Additional Year Completely FREE. Don't miss out on this exclusive offer. Claim Your Free Year →